产品
编 号：F308219
分子式：C25H25N3O5
分子量：447.48
分子式：C25H25N3O5
分子量：447.48
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 292618-32-7
产品详情
生物活性：
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.
体内研究：
Gimatecan (2 mg/kg; treatment per os, every fourth day for four times) is effective for inhibiting tumor growth.Animal Model:Athymic Swiss nude mice bearing HT1376 model
Dosage:2 mg/kg
Administration:Treatment per os, every fourth day for four times
Result:Caused a marked tumor growth inhibition during treatment.
体外研究：
Gimatecan (3 to 300 ng/mL) significantly inhibits the growth of human bladder cancer models (HT1376 and MCR), thus reflecting antiproliferative potency.Gimatecan causes a persistent S-phase arrest At 0.003 μg/mL and the number of S-phase cells increased after treatment with a higher concentration (0.03 μg/mL).
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.
体内研究：
Gimatecan (2 mg/kg; treatment per os, every fourth day for four times) is effective for inhibiting tumor growth.Animal Model:Athymic Swiss nude mice bearing HT1376 model
Dosage:2 mg/kg
Administration:Treatment per os, every fourth day for four times
Result:Caused a marked tumor growth inhibition during treatment.
体外研究：
Gimatecan (3 to 300 ng/mL) significantly inhibits the growth of human bladder cancer models (HT1376 and MCR), thus reflecting antiproliferative potency.Gimatecan causes a persistent S-phase arrest At 0.003 μg/mL and the number of S-phase cells increased after treatment with a higher concentration (0.03 μg/mL).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备